GlassScriptPhysician profile
Orlee Hamer
NPI 1922390574
$1,629.11
in general payments reported to CMS, 2019-2025
24 companies · $575 in 2025
The $575 reported for 2025 was more than what 81% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74.31 · 2020: $54.57 · 2021: $21.49 · 2022: $163 · 2023: $397 · 2024: $344 · 2025: $575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,315.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $471.58 | 2019-2025 | Belbuca, Xtampza |
| Boston Scientific Corporation | $220.37 | 2019-2025 | General - Pain Management, Wavewriter Alpha Prime 16 |
| Medtronic, INC. | $135.23 | 2021-2025 | Intellis Adaptivestim, Inceptiv |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $130.14 | 2023-2025 | Relistor |
| Abbvie INC. | $97.61 | 2022-2025 | |
| Valinor Pharma, LLC | $67.15 | 2024-2025 | Movantik |
| Janssen Pharmaceuticals, INC | $56.81 | 2022-2024 | Spravato |
| Smith+Nephew, INC. | $45.54 | 2023 | Pico |
| Nevro Corp. | $39.70 | 2020 | |
| Globus Medical, INC. | $38.43 | 2025 | Senza |
| Averitas Pharma INC. | $38.33 | 2023-2024 | Qutenza |
| Mml US, INC. | $34.90 | 2025 | Reactiv8 |
| Forte Bio-Pharma LLC | $33.99 | 2025 | Prolate, Tanlor, Nalocet |
| Protega Pharmaceutials INC | $32.76 | 2023-2024 | Roxybond |
| Zyla Life Sciences, INC. | $24.74 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioventus LLC | $22.62 | 2022 | |
| Hikma Pharmaceuticals USA | $21.00 | 2022 | |
| Saluda Medical Americas, INC. | $20.10 | 2023 | Evoke Scs |
| Nalu Medical, INC. | $19.45 | 2024 | Nalu Neurostimulation System |
| Abbott Laboratories | $18.88 | 2025 | Proclaim |
| Pacira Pharmaceuticals Incorporated | $15.73 | 2023 | Zilretta, Iovera, Exparel |
| Redhill Biopharma INC. | $15.00 | 2022 | |
| Ferring Pharmaceuticals INC. | $14.64 | 2022 | |
| Sanofi-Aventis U.S. LLC | $14.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Orlee Hamer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.